Diffuse midline glioma, H3 K27M-mutant
Clinical trials for Diffuse midline glioma, H3 K27M-mutant explained in plain language.
Never miss a new study
Get alerted when new Diffuse midline glioma, H3 K27M-mutant trials appear
Sign up with your email to follow new studies for Diffuse midline glioma, H3 K27M-mutant, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells delivered directly to the brain show promise for kids with deadly tumors
Disease control OngoingThis early-stage trial tests a new treatment for children and young adults up to age 21 with certain brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a pro…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New brain cancer drug shows promise in early trial
Disease control PausedThis early-phase study tests whether adding a drug called S-Gboxin to standard treatment can help people with glioblastoma, a fast-growing brain cancer. The drug works by cutting off the energy supply to cancer cells. Ten patients with recurrent or progressive disease will receiv…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase 1 • Sponsor: Petrov, Andrey • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could two weeks of radiation be as good as six for this brain cancer?
Symptom relief OngoingThis study is for people with a rare and aggressive brain tumor called diffuse midline glioma. Instead of the usual six weeks of daily radiation, researchers are testing a shorter course of just two weeks. The goal is to see if the shorter treatment works just as well at controll…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC